Hematology, Transfusion and Cell Therapy (Apr 2023)

GATA2 variants in patients with non-tuberculous mycobacterial or fungal infections without known immunodeficiencies

  • Daniela P. Mendes-de-Almeida,
  • Francianne G. Andrade,
  • Filipe V. dos Santos-Bueno,
  • Dayvison F. Saraiva Freitas,
  • Sheila C. Soares-Lima,
  • Rosely M. Zancopé-Oliveira,
  • Maria S. Pombo-de-Oliveira

Journal volume & issue
Vol. 45, no. 2
pp. 211 – 216

Abstract

Read online

ABSTRACT: Introduction: Haploinsufficiency of the hematopoietic transcription factor GATA2 is associated with a broad spectrum of diseases, including infection susceptibility and neoplasms. We aimed to investigate GATA2 variants in patients with non-tuberculous mycobacterial (NTM) and/or fungal infections (FI) without known immunodeficiencies. Method: We performed GATA2 genotyping in patients with NTM and/or FI. Results: Twenty-two patients were enrolled (seventeen FI, four NTM and one with both infections). The pathogenic variant NG_029334.1:g.16287C>T was found in one patient (4.5%) and two asymptomatic offsprings. We also found the likely-benign variant NG_029334.1:g.12080G>A (rs2335052), the benign variant NG_029334.1:g.16225C>T (rs11708606) and the variant of uncertain significance NG_029334.1:g.16201G>A (rs369850507) in 18.2%, 27.3%, and 4.5% of the cases, respectively. Malignant diseases were additionally diagnosed in six patients. Conclusion: Although detected in 45.4% of the patients, most GATA2 variants were benign or likely benign. Identifying a pathogenic variant was essential for driving both the patient's treatment and familial counseling. Pathogenic variants carriers should receive genetic counseling, subsequent infection prevention measures and malignancies surveillance. Additionally, case-control genotyping should be carried out in Brazil to investigate whether the observed variants may be associated with susceptibility to opportunistic infections and/or concurrent neoplasms.

Keywords